Cataract Surgery clinical trials

Explore recruiting cataract surgery clinical trials.

Recruiting cataract surgery studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cataract Surgery trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12 Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy

Germany, Denmark, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Cataract surgery and Inflammation – the role for preoperative NSAIDs (pre-CIN)

Norway

Therapeutic use (Phase IV) EU CTIS Study details

Comparison of treatment with preservative-free dexamethasone 0.1% (Monofree Dexamethason) and diclofenac 0.1% (Dicloabak) eye drops versus preserved dexamethasone 0.1% (Maxidex) and diclofenac 0.1% (Voltaren Ophtha) eye drops after cataract surgery.

Belgium

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% in the treatment of inflammation after cataract surgery in pediatric population 0 to 3 years of age (CLOSE-3).

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Effect of nepafenac/dexamethasone fixed dose combination vs. its individual components (nepafenac and dexamethasone monotherapies) on postoperative inflammation after cataract surgery: a randomized, multicentre, blinded-assessor, parallel-group clinical study – NE.DE.F. STUDY

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

MyKid-study: efficacy and systemic side effects of intracameral Mydrane® injections in children undergoing cataract surgery.

Belgium

Therapeutic use (Phase IV) EU CTIS Study details

Cataract Surgery trials by city

Cataract Surgery in Toronto Cataract Surgery in Vancouver Cataract Surgery in Montreal Cataract Surgery in Calgary Cataract Surgery in Edmonton Cataract Surgery in Ottawa Cataract Surgery in Winnipeg Cataract Surgery in Quebec City Cataract Surgery in Hamilton Cataract Surgery in Kitchener Cataract Surgery in London Cataract Surgery in Halifax Cataract Surgery in New York Cataract Surgery in Los Angeles Cataract Surgery in Chicago Cataract Surgery in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease